Daniel Castellano

👩‍🔬👨‍🔬 Encuentro de investigadores en cáncer del #Hospital12deOctubre con un grupo de pacientes. 🤝 Organizado con @ContraCancerEs. 🎬 Proyección del documental 'Conectando Vidas', grabado íntegramente en el #H12O. ⏯ Dale al play: c.madrid/73i0c #somosdel12

MITO vs REALIDAD  ❌ La medicina de precisión solo es útil en enfermedad avanzada.  ✅ El uso de biomarcadores y herramientas moleculares está ampliando progresivamente su papel en diferentes momentos del abordaje clínico.  La investigación continúa redefiniendo la práctica asistencial.  #PrecisionOncology #GUARDConsortium @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1

🚨 The OncoAlert #BreastCancer faculty’s TOP 10 abstracts for #ASCO26 — selected by our leads and finalized through a Delphi voting process with senior breast cancer experts. 1️⃣ 500 — OPTIMA Test-directed chemotherapy in high-risk ER+/HER2- early BC 2️⃣ LBA1006 — PERSEVERA BC Giredestrant + palbociclib vs letrozole + palbociclib in 1L ER+/HER2- LA/MBC 3️⃣ 507 — KEYNOTE-522 final analysis Perioperative pembrolizumab in high-risk early TNBC 4️⃣ LBA1007 — SERENA-6 1L camizestrant for emergent ESR1 mutations — final PFS2 5️⃣ 502 — LIDERA BC Giredestrant in ER+/HER2- early BC by menopausal status 6️⃣ LBA1000 — ASCENT-04 SG + pembrolizumab vs chemo + pembrolizumab in 1L PD-L1+ mTNBC 7️⃣ 501 — NATALEE biomarker analysis Baseline gene expression and adjuvant ribociclib benefit 8️⃣ LBA503 — SENOMAC Omission of axillary dissection: OS + arm morbidity 9️⃣ 1001 — ASCENT-03 SG vs chemotherapy in 1L mTNBC — PFS2 🔟 LBA1003 Izalontamab brengitecan vs physician’s choice chemo in metastatic TNBC Leads🚨 @ElisaAgostinett @to_be_elizabeth @WeOncologists Senior Faculty @ErikaHamilton9 @E_de_Azambuja @matteolambe @DrSGraff @hoperugo @BianchiniGP Dr. Bidard @Icro_Meattini Participating AF @Lucarecco @GaiaGriguolo Ping Faculty @aftimosp @double_whammied @stage4kelly @coffeemommy @itsnot_pink @maryam_lustberg @IBCResearch @kevinpunie @nicolobattisti @raalbany @teamoncology @stolaney1 @LoiSher @SirohiBhawna @chemobrainfog @jamecancerdoc @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @paspears88 @MammaMiaMagazin @itrisabel

💡 ¿Sabías que uno de los grandes retos actuales en #oncologíaGU ya no es solo desarrollar nuevas terapias? La innovación avanza rápidamente gracias a la inmunoterapia, las terapias dirigidas y la medicina de precisión, pero conseguir que estos avances lleguen al paciente adecuado en el momento adecuado sigue siendo un desafío. La investigación colaborativa y la evidencia en práctica clínica real serán clave para reducir esta brecha. 🔬 #GUARDConsortium #GUOncology #PrecisionMedicine #Innovación @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1

The OncoAlert🚨 GU faculty’s TOP 10 abstracts In GU Oncology for #ASCO26 are here — selected by our leads and finalized through a Delphi voting process with our senior GU cancer experts across #ProstateCancer #KidneyCancer #BladderCancer . A snapshot of what will shape GU oncology at #ASCO26 👇 1️⃣ LBA5007 — TALAPRO-3 Talazoparib + enzalutamide vs placebo + enzalutamide in mCSPC with HRR alterations 2️⃣ LBA1 — PROTEUS Perioperative apalutamide + ADT vs ADT in high-risk localized/locally advanced prostate cancer (final Phase 3) 3️⃣ 5001 — ENZAMET genomic analysis Decipher >0.85 to identify benefit from adding docetaxel to ADT + enzalutamide 4️⃣ LBA4511 — KEYNOTE-564 ctDNA ctDNA dynamics in RCC treated with adjuvant pembrolizumab vs placebo 5️⃣ 4502 — RAMPART Durvalumab vs active monitoring after resection in RCC (Phase 3 RCT) 6️⃣ 4500 — RADICAL (A031801) Radium-223 + cabozantinib in RCC with bone metastases 7️⃣ 4507 — EV-302 long-term follow-up Enfortumab vedotin + pembrolizumab vs chemotherapy in 1L LA/mUC 8️⃣ 4513 — AMBASSADOR (A031501) HRQoL with adjuvant pembrolizumab vs observation in high-risk MIBC 9️⃣ 4503 — SAKK 06/19 Perioperative intravesical rBCG + chemo-IO strategy in MIBC (primary analysis) 🔟 4510 — KEYNOTE-905 HRQoL with perioperative enfortumab vedotin + pembrolizumab in cisplatin-ineligible MIBC Leads @nataliagandur @scocmem @AmandaNizamMD @WeOncologists Senior Faculty @montypal @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @neerajaiims @amerseburger @Silke_Gillessen @tompowles1 @AndreaNecchi @cdanicas @AOmlin Pinging @crisbergerot @HHammersMD @ravikanesvaran @sonpavde @drenriquegrande @scserendipity1 @EfstathiouEleni @BraunMDPhD @brian_rini

👏👏 Great game amigo!! And excelente team!!🏆

🚨 OncoAlert GU Faculty TOP 🔟 abstracts in GU Oncology for #ASCO26 Truly honored and proud to be among the Leads 🗺 Selected by our leads and finalized through a Delphi voting process with senior GU experts across 🌎🌏🌍 #ProstateCancer #KidneyCancer #BladderCancer. 💛 A snapshot of what will shape GU oncology at #ASCO26, and what we all hope will translate into better, more thoughtful care for our patients 👇 1️⃣ LBA5007 — TALAPRO-3 Talazoparib + enzalutamide vs placebo + enzalutamide in mCSPC with HRR alterations 2️⃣ LBA1 — PROTEUS (final Phase 3) Perioperative apalutamide + ADT vs ADT in high-risk localized/locally advanced prostate cancer 3️⃣ 5001 — ENZAMET genomic analysis Decipher >0.85 to identify benefit from adding docetaxel to ADT + enzalutamide 4️⃣ LBA4511 — KEYNOTE-564 ctDNA (RCC) ctDNA dynamics in RCC treated with adjuvant pembrolizumab vs placebo 5️⃣ 4502 — RAMPART (Phase 3 RCT, RCC) Durvalumab vs active monitoring after resection in RCC 6️⃣ 4500 — RADICAL (A031801, RCC bone mets) Radium-223 + cabozantinib in RCC with bone metastases 7️⃣ 4507 — EV-302 long-term follow-up (LA/mUC) Enfortumab vedotin + pembrolizumab vs chemotherapy in 1L LA/mUC 8️⃣ 4513 — AMBASSADOR (A031501, MIBC) HRQoL with adjuvant pembrolizumab vs observation in high-risk MIBC 9️⃣ 4503 — SAKK 06/19 (MIBC) Perioperative intravesical rBCG + chemo-IO strategy (primary analysis) 🔟 4510 — KEYNOTE-905 (cisplatin-ineligible MIBC) HRQoL with perioperative enfortumab vedotin + pembrolizumab ✨ Recurring theme: precision intensification 🧬 + ctDNA integration 🩸 + patient-centered outcomes (QoL) 🧠 + practice-changing frontline standards 🔥 And the key question: how do we implement this thoughtfully and equitably in real-world care? Leads @nataliagandur @scocmem @AmandaNizamMD @WeOncologists Senior Faculty @montypal @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @neerajaiims @amerseburger @Silke_Gillessen @tompowles1 @AndreaNecchi @cdanicas @AOmlin Pinging @crisbergerot @HHammersMD @ravikanesvaran @sonpavde @drenriquegrande @scserendipity1 @EfstathiouEleni @BraunMDPhD @brian_rini #GUOncology #OncoAlert #ASCO26 #KidneyCancer #BladderCancer #ProstateCancer

Ab#4519 @ASCO #ASCO26 by @RWinayak👉 bit.ly/49bkMX4👉Addition of CBM588 to ICB-based 1L combinations in mRCC #kidneycancer👉dysbiotic stool confers greater benefit & a potential biomarker👉Ph3 @SWOG BIOFRONT ongoing👇@montypal @nazlidizman @OncoAlert @urotoday @kidneycan

Ab#4576 @ASCO #ASCO26 by @SalvadorjcMD👉 bit.ly/4nL57np👉172 pts w/ aUCtreated w/ EV based Rx #bladdercancer👉Rx breaks (TB) did not compromise outcomes👉had longer PFS (p=0.05) & OS (p=0.008)👉need de-escalation trials👉@montypal @AbhiTrip87 @oncoalert @urotoday

Ab#5014 @ASCO #ASCO26 by @TDorffOnc👉 bit.ly/4dCHnNv 👉Ph1 study of PSMA/STEAP1 dual-targeting ADC ABBV-969 in mCRPC #prostatecancer 👉Encouraging efficacy👉PSA50 67%, dose optimizing ongoing👇 @OncoAlert @urotoday @PCF_science @OpenMedicineHQ

Ab#5020 @ASCO #ASCO26 by #FredSaad👉 bit.ly/3RrwTsQ👉subgroup analyses in PSMAddition #prostatecancer👉Lu-177+ADT+ARPI⬆️rPFS vs ADT+ARPI across high/low vol & de novo/recurrent PSMA+ mHSPC👇@OncoAlert @urotoday @PCF_science @DrScottTagawa @mishabeltran @OpenMedicineHQ

Ab#5016 @ASCO #ASCO26 by @AarmstrongDuke @Daniel_J_George👉bit.ly/4utyM74👉Ph2 trial of chemo-IO for NEPC/aggressive variant PC #prostatecancer👉6-mo PFS 78%, OS 12 mo👉ICI+platinum shows⬆️efficacy vs historic platinum alone👇@OncoAlert @urotoday @PCF_science

Ab#5060 @ASCO #ASCO26 by @ggebraelmd @Huntsman_GU👉bit.ly/4uXfExT👉Ph1b Rad2Nivo trial👉Radium for 2 cycles followed by Nivo/Radium for 4 cycles followed by Nivo alone➡️60% of pts w/ mean ctDNA VAF reduction #prostatecancer👇@maughanonc @OncoAlert @urotoday @PCF_Science

Ab#5096 @ASCO #ASCO26 by @ggebraelmd👉 bit.ly/3RTHBsc👉Post hoc analysis of @swog 1216 ph3👉Baseline testosterone (≤ vs > median) does not associate w/ outcomes in pts w/ mHSPC #prostatecancer👉baseline T may not assist w/ prognostication👇@OncoAlert @urotoday

Ab#5011 @ASCO #ASCO26 by #MichaelMorris @Eantonarakis👉bit.ly/49WW8cL👉Ac-225 (CONV01-ɑ) in Lu-pretreated mCRPC #prostatecancer👉CONV01-ɑ well-tolerated & 45.4% (5/11) of pts had PSA50👉pivotal study is planned👇 @OncoAlert @urotoday @PCF_science @OpenMedicineHQ

👏👏 open the door of new perspectives in prostate cancer!

Dear Colleagues, As #ASCO26 descends on Chicago, @OncoAlert 🚨 is proud to introduce the OncoAlert PULSE Faculty 🩺 — your frontline team for every breakthrough, every result, every moment. Live. As it happens. @DrChoueiri 🇺🇸 @hoperugo 🇺🇸 @matteolambe 🇮🇹 @TiansterZhang 🇺🇸 @cdanicas 🇪🇸 @NiuSanford 🇺🇸 @amerseburger 🇩🇪 @GlopesMd 🇺🇸 @Icro_Meattini 🇮🇹 @PGrivasMDPhD 🇺🇸 @DrYukselUrun 🇹🇷 @nataliagandur 🇦🇷 @ElisaAgostinett 🇧🇪 @HHorinouchi 🇯🇵 @realbowtiedoc 🇺🇸 @to_be_elizabeth 🇮🇹 @UOzkerim🇹🇷 @p_ciracimd 🇮🇹 @DrVilmaPBarcia 🇪🇸 @DraMartinezLago @GaiaGriguolo 🇮🇹 @MarioBalsaMD 🇪🇸 @scocmem 🇬🇧 @AmandaNizamMD 🇺🇸 & @weoncologists 🇺🇸

We are getting Closer #OncoAlert5k 🏃‍♂️‍➡️ at #ASCO26 Are you Ready?? Join US!!! May 30th, 2026 7am SIGN UP HERE 👉 buff.ly/3kvnMej @nataliagandur @acampsmalea @BRicciutiMD @yekeduz_emre @HHorinouchi @FadiHaddad_MD @Dr_Ivanoncologo @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @matteolambe @PGrivasMDPhD @cdanicas @BenWestphalen @Latinamd @ShaalanBeg @rowela_pfizer @LaurenMachos @milosicevic @COR2EDMedEd @VJOncology @mirrorsmed @JooMouta2 @graokane

Desde GUARD hoy estamos presentes en Valencia en la II Jornada para Pacientes con Cáncer de Vejiga de @CANVES_ES  El Dr. Ignacio Durán @nachoduranm participa en representación de #GUARDConsortium en la mesa redonda: 🗣️ La relación de las Sociedades Científicas con las Asociaciones de Pacientes Moderada por la Dra. María José Juan @mjuanfi81 #UroOncology

The predictive role of [177Lu]Lu-PSMA-617 SPECT/CT semiquantitative parameters from the 1st RLT cycle in advanced mCRPC: a preliminary bicentric lesion-based analysis link.springer.com/article/10.100… This retrospective study evaluated whether semiquantitative SPECT/CT parameters from the first cycle of [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy can predict lesion-level response in metastatic castration-resistant #ProstateCancer . In 23 patients with 290 lesions, higher SUVmax, SUVmean, TLV, and especially total lesion activity were associated with non-progressing lesions. ROC analysis showed good predictive performance for TLA and SUV metrics, suggesting early imaging biomarkers may help anticipate individual lesion response to PSMA-targeted therapy @MBauckneht @OncoAlert 🚨 @Silke_Gillessen @AOmlin @weoncologists